530125 — Samrat Pharmachem Share Price
- IN₹1.09bn
- IN₹1.08bn
- IN₹2.82bn
- 32
- 37
- 38
- 24
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.64 | ||
Price to Tang. Book | 1.64 | ||
Price to Free Cashflow | 12.17 | ||
Price to Sales | 0.38 | ||
EV to EBITDA | 42.59 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 2.79% | ||
Return on Equity | 3.38% | ||
Operating Margin | 0.65% |
Financial Summary
Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | IN₹m | 1,374.52 | 1,790.18 | 2,218.12 | 3,106.46 | 2,815.81 | n/a | n/a | 20.43% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +176.48 | +25.92 | +221.77 | -3.32 | -87 | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Samrat Pharmachem Limited is an India-based company, which is engaged in the manufacturing and selling of pharmaceutical chemicals. The Company is a supplier of iodine derivatives to the Indian and foreign market. The Company’s products include 3-5-Di Iodosalicylic Acid, Ammonium Iodide, Calcium Iodide, Clioquinol, Copper Iodide, Ethyl Iodide, Ethylenediamine Dihydroiodide, Hydroiodic Acid 57%, Iodic Acid, Iodine, Iodine Monochloride, Iodoquinol, Lithium Iodide, Methyl Iodide, N-Iodo Succcinimide, Periodic Acid, Potassium Iodate, Potassium Iodide, Potassium Metaper Iodate, Povidone Iodine, Selenium Dioxide, Sodium Iodate, Sodium Iodide, Sodium Metaper Iodate, Sodium Selenite, Tetra Butyl Ammonium Iodide, and Tri Methyl Sulphoxonium Iodide. It serves various industries, such as agrochemical, animal feed, chemicals, food, pharmaceutical, printing, and textile. The Company exports its products to various countries, including United States, Europe, Africa, Asia, and Middle East.
Directors
- Lalit Mehta CHM (76)
- Nishant Kankaria CCO
- Megh Mehta EDR (24)
- Rajesh Mehta EDR (53)
- Renu Dharod NID
- Samir Kothary NID (56)
- Mahendra Pipalia NID (55)
- Last Annual
- March 31st, 2024
- Last Interim
- March 31st, 2024
- Incorporated
- June 16th, 1992
- Public Since
- February 28th, 1995
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Bombay Stock Exchange
- Shares in Issue
- 3,089,700
![Blurred out image of a map](https://www.stockopedia.com/assets/conversion/images/maps_placeholder.jpg)
- Address
- 701/702, MUMBAI, 400058
- Web
- https://www.samratpharmachem.com/
- Phone
- +91 2226701050
- Auditors
- Shah & Savla LLP
Upcoming Events for 530125
Samrat Pharmachem Ltd Annual Shareholders Meeting
Q2 2025 Samrat Pharmachem Ltd Earnings Release
Similar to 530125
Achyut Healthcare
Bombay Stock Exchange
Adline Chem Lab
Bombay Stock Exchange
MPS Pharmaa
Bombay Stock Exchange
Albert David
Bombay Stock Exchange
Ambalal Sarabhai Enterprises
Bombay Stock Exchange
FAQ
As of Today at 17:05 UTC, shares in Samrat Pharmachem are trading at IN₹344.55. This share price information is delayed by 15 minutes.
Shares in Samrat Pharmachem last closed at IN₹344.55 and the price had moved by -19.23% over the past 365 days. In terms of relative price strength the Samrat Pharmachem share price has underperformed the S&P BSE 100 Index by -38.29% over the past year.
There is no consensus recommendation for this security.
The Samrat Pharmachem dividend yield is 0.29% based on the trailing twelve month period.
Last year, Samrat Pharmachem paid a total dividend of IN₹1.00, and it currently has a trailing dividend yield of 0.29%. We do not have any data on when Samrat Pharmachem is to next pay dividends.
We do not have data on when Samrat Pharmachem is to next pay dividends. The historic dividend yield on Samrat Pharmachem shares is currently 0.29%.
To buy shares in Samrat Pharmachem you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹344.55, shares in Samrat Pharmachem had a market capitalisation of IN₹1.06bn.
Here are the trading details for Samrat Pharmachem:
- Country of listing: India
- Exchange: BSE
- Ticker Symbol: 530125
Based on an overall assessment of its quality, value and momentum Samrat Pharmachem is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Samrat Pharmachem. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -12.18%.
As of the last closing price of IN₹344.55, shares in Samrat Pharmachem were trading -7.47% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Samrat Pharmachem PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹344.55.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Samrat Pharmachem's management team is headed by:
- Lalit Mehta - CHM
- Nishant Kankaria - CCO
- Megh Mehta - EDR
- Rajesh Mehta - EDR
- Renu Dharod - NID
- Samir Kothary - NID
- Mahendra Pipalia - NID